{"pmid":32352362,"title":"Management strategies for patients with autoimmune diseases during the COVID-19 pandemic: A perspective from China.","text":["Management strategies for patients with autoimmune diseases during the COVID-19 pandemic: A perspective from China.","Eur J Rheumatol","Liu, Yu","Chang, Christopher","Lu, Qianjin","32352362"],"journal":"Eur J Rheumatol","authors":["Liu, Yu","Chang, Christopher","Lu, Qianjin"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32352362","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.5152/eurjrheum.2020.2056","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666138495659278338,"score":9.490897,"similar":[{"pmid":32420788,"title":"Management Strategies of Autoimmune bullous diseases during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19).","text":["Management Strategies of Autoimmune bullous diseases during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19).","Since late December 2019, an outbreak of the novel coronavirus disease, which is mainly characterized by pulmonary lesions, has spread quickly worldwide. With the spread of the novel coronavirus, the outpatient lines of hospitals have mostly shut down, which means that routine clinical diagnosis and treatment for autoimmune bullous diseases patients have been disturbed. Due to the serious condition of autoimmune bullous diseases patients, they are prone to immune suppression and circulatory failure, and are more susceptible to infection than healthy individuals. These patients should thus be a priority group for novel coronavirus disease prevention. In this context, the protection and control measures for autoimmune bullous diseases patients against the novel coronavirus are of serious concern. Clinicians should strengthen their communication with patients, pay attention to changes in patients' conditions, and carefully adjust the treatment strategy, while protecting against the novel coronavirus infection, to ensure the continuity, safety, and effectiveness of autoimmune bullous diseases treatment.","J Dermatolog Treat","Chen, Pan","Zhang, Guiying","Zhan, Yi","32420788"],"abstract":["Since late December 2019, an outbreak of the novel coronavirus disease, which is mainly characterized by pulmonary lesions, has spread quickly worldwide. With the spread of the novel coronavirus, the outpatient lines of hospitals have mostly shut down, which means that routine clinical diagnosis and treatment for autoimmune bullous diseases patients have been disturbed. Due to the serious condition of autoimmune bullous diseases patients, they are prone to immune suppression and circulatory failure, and are more susceptible to infection than healthy individuals. These patients should thus be a priority group for novel coronavirus disease prevention. In this context, the protection and control measures for autoimmune bullous diseases patients against the novel coronavirus are of serious concern. Clinicians should strengthen their communication with patients, pay attention to changes in patients' conditions, and carefully adjust the treatment strategy, while protecting against the novel coronavirus infection, to ensure the continuity, safety, and effectiveness of autoimmune bullous diseases treatment."],"journal":"J Dermatolog Treat","authors":["Chen, Pan","Zhang, Guiying","Zhan, Yi"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420788","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/09546634.2020.1771261","keywords":["autoimmune bullous diseases","covid-19","patient management","personal protection"],"topics":["Prevention"],"weight":1,"_version_":1667159284438269953,"score":45.43647},{"pmid":32283134,"pmcid":"PMC7151539","title":"Highlights for management of patients with Autoimmune Liver Disease during COVID-19 pandemia.","text":["Highlights for management of patients with Autoimmune Liver Disease during COVID-19 pandemia.","J Hepatol","Lleo, Ana","Invernizzi, Pietro","Lohse, Ansgar W","Aghemo, Alessio","Carbone, Marco","32283134"],"journal":"J Hepatol","authors":["Lleo, Ana","Invernizzi, Pietro","Lohse, Ansgar W","Aghemo, Alessio","Carbone, Marco"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283134","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jhep.2020.04.002","keywords":["autoimmune hepatitis","autoimmune liver diseases","covid-19","immunosuppressive therapy"],"topics":["Prevention"],"weight":1,"_version_":1666138491498528770,"score":42.024418},{"pmid":32333823,"title":"Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.","text":["Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.","Autoimmune bullous diseases (AIBDs) are potentially life-threatening disorders comprising intra-epidermal/epithelial (pemphigus) and sub-epidermal/epithelial blistering diseases (pemphigoid and dermatitis herpetiformis). Corticosteroids and non-steroid immunomodulatory agents are the mainstays of treatment. Treatment can be challenging particularly in pemphigus, mucous membrane pemphigoid, and epidermolysis bullosa acquisita which may require more intense immunosuppressive approaches.","J Eur Acad Dermatol Venereol","Kasperkiewicz, M","Schmidt, E","Fairley, J A","Joly, P","Payne, A S","Yale, M L","Zillikens, D","Woodley, D T","32333823"],"abstract":["Autoimmune bullous diseases (AIBDs) are potentially life-threatening disorders comprising intra-epidermal/epithelial (pemphigus) and sub-epidermal/epithelial blistering diseases (pemphigoid and dermatitis herpetiformis). Corticosteroids and non-steroid immunomodulatory agents are the mainstays of treatment. Treatment can be challenging particularly in pemphigus, mucous membrane pemphigoid, and epidermolysis bullosa acquisita which may require more intense immunosuppressive approaches."],"journal":"J Eur Acad Dermatol Venereol","authors":["Kasperkiewicz, M","Schmidt, E","Fairley, J A","Joly, P","Payne, A S","Yale, M L","Zillikens, D","Woodley, D T"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333823","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jdv.16525","keywords":["covid-19","sars-cov-2","pemphigoid","pemphigus"],"e_drugs":["Steroids"],"topics":["Prevention"],"weight":1,"_version_":1666138494048665600,"score":41.54679},{"pmid":32348045,"title":"[Autoimmune diseases in the context of pandemic COVID-19].","text":["[Autoimmune diseases in the context of pandemic COVID-19].","Patient suffering from autoimmune diseases (AID) typically have an increased risk of infection, which is attributed to the disease itself, but also to immunosuppressive drugs (IS) and comorbidities. During the current COVID-19 outbreak, the way to manage these diseases remains elusive. Limited data is currently available on AID and IS in the context of this new coronavirus infection. To date, there is no evidence to support an increase in complications of COVID-19 in these patients. In addition, certain drugs that are commonly used to treat AID could be part of the therapeutic arsenal used in COVID-19. The purpose of this article is to review the unique aspects of patients with AID during the COVID-19 outbreak.","Rev Med Suisse","Horisberger, Alice","Moi, Laura","Ribi, Camillo","Comte, Denis","32348045"],"abstract":["Patient suffering from autoimmune diseases (AID) typically have an increased risk of infection, which is attributed to the disease itself, but also to immunosuppressive drugs (IS) and comorbidities. During the current COVID-19 outbreak, the way to manage these diseases remains elusive. Limited data is currently available on AID and IS in the context of this new coronavirus infection. To date, there is no evidence to support an increase in complications of COVID-19 in these patients. In addition, certain drugs that are commonly used to treat AID could be part of the therapeutic arsenal used in COVID-19. The purpose of this article is to review the unique aspects of patients with AID during the COVID-19 outbreak."],"journal":"Rev Med Suisse","authors":["Horisberger, Alice","Moi, Laura","Ribi, Camillo","Comte, Denis"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348045","source":"PubMed","week":"202018|Apr 27 - May 03","topics":["Prevention","Treatment"],"weight":1,"_version_":1666138494949392387,"score":40.481487}]}